Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies

Berardino De Bari, Andrea Riccardo Filippi, Rosario Mazzola, Pierluigi Bonomo, Marco Trovò, Lorenzo Livi, Filippo Alongi

Research output: Contribution to journalArticlepeer-review

Abstract

Patients affected with intra-thoracic recurrences of primary or secondary lung malignancies after a first course of definitive radiotherapy have limited therapeutic options, and they are often treated with a palliative intent. Re-irradiation with stereotactic ablative radiotherapy (SABR) represents an appealing approach, due to the optimized dose distribution that allows for high-dose delivery with better sparing of organs at risk. This strategy has the goal of long-term control and even cure. Aim of this review is to report and discuss published data on re-irradiation with SABR in terms of efficacy and toxicity. Results indicate that thoracic re-irradiation may offer satisfactory disease control, however the data on outcome and toxicity are derived from low quality retrospective studies, and results should be cautiously interpreted. As SABR may be associated with serious toxicity, attention should be paid for an accurate patients' selection.

Original languageEnglish
Pages (from-to)511-518
Number of pages8
JournalCancer Treatment Reviews
Volume41
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Keywords

  • Lung cancer
  • Re-irradiation
  • Stereotactic ablative radiotherapy
  • Stereotactic body radiotherapy
  • Thoracic relapse

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies'. Together they form a unique fingerprint.

Cite this